论文部分内容阅读
参考Troost法检测了肝细胞癌(HCC)及其他肝脏占位性病变和疾病患者血清和组织中的α-L-岩藻糖甙酶(AFU)活性。结果表明:血清AFU活性测定对HCC诊断的敏感性和特异性分别为81.2%和83.3%。对甲胎蛋白阴性和早期HCC诊断敏感性亦分别达76.1%和70.8%。HCC组织及其癌周肝组织中AFU活性明显高于对照组近1倍,且与相应血清中的活性升高相一致(r=0.742,P<0.01)。提示AFU可能是HCC的新型生物学标记物,对HCC的诊断有重要价值。
The Troost assay was used to detect α-L-fucosidase (AFU) activity in serum and tissues of patients with hepatocellular carcinoma (HCC) and other liver space-occupying lesions and diseases. The results showed that the sensitivity and specificity of serum AFU activity assay for the diagnosis of HCC were 81.2% and 83.3%, respectively. The sensitivity to alpha-fetoprotein-negative and early-stage HCC was also 76.1% and 70.8%, respectively. The activity of AFU in HCC tissue and its surrounding liver tissue was significantly higher than that in the control group, and was consistent with the increase in activity in the corresponding serum (r=0.742, P<0.01). It suggests that AFU may be a novel biomarker for HCC and is of great value in the diagnosis of HCC.